Medical and Regulatory Affairs
The FDA’s New Guidance on Natural History Studies in Rare Diseases: What You Need to Know
In March 2019, the FDA released draft guidance on the design and implementation of natural history studies to support the development of safe and effective treatments for rare diseases. The document, Rare Diseases: Natural History Studies for Drug Development,[1] addresses one of the major challenges sponsors encounter when developing therapies for rare disease: the lack...